Revolution Medicines (RVMD) Interest Expenses (2019 - 2026)

Revolution Medicines' Interest Expenses history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Interest Expenses rose 584.85% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 584.85% increase from a year earlier, with the FY2025 full-year figure at $885.5 million, up 220.44% from the prior year.
• Interest Expenses improved to $1.2 billion in Q1 2026 per RVMD's latest filing, from -$12.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $1.2 billion in Q1 2026 and bottomed at -$12.3 million in Q4 2025.
• The 5-year median for Interest Expenses is $131.4 million (2023), against an average of $206.8 million.
• Across the five-year window, Interest Expenses plunged 336.38% in 2025 and jumped 584.85% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $91.4 million in 2022, then soared by 101.51% to $184.2 million in 2023, then tumbled by 101.52% to -$2.8 million in 2024, then plunged by 336.38% to -$12.3 million in 2025, then soared by 9636.02% to $1.2 billion in 2026.
• Per Business Quant, the three latest RVMD Interest Expenses figures stand at $1.2 billion (Q1 2026), -$12.3 million (Q4 2025), and $328.1 million (Q3 2025).